PMID- 27698361
OWN - NLM
STAT- MEDLINE
DCOM- 20180710
LR  - 20181113
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 6
DP  - 2016 Oct 4
TI  - Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in 
      First-episode Treatment-naive Schizophrenia Patients: A Longitudinal fMRI Study.
PG  - 34287
LID - 10.1038/srep34287 [doi]
LID - 34287
AB  - It is unclear whether abnormal spontaneous neural activation patterns found in 
      chronic schizophrenia patients (CSP) are part of the pathogenesis of disease, 
      consequences of chronic illness, or effects of antipsychotic treatment. We 
      performed a longitudinal resting-state functional magnetic resonance imaging 
      (fMRI) study in 42 treatment-naive first-episode schizophrenia patients (FESP) at 
      baseline and then after 8-weeks of risperidone monotherapy, and compared the 
      findings to 38 healthy volunteers. Spontaneous brain activity was quantified 
      using the fractional amplitude of low-frequency fluctuations (fALFF) and regional 
      homogeneity (ReHo) and compared between patients and controls. Pretreatment, 
      patients exhibited higher fALFF in left caudate compared with controls. After 
      treatment, patients had elevated fALFF in bilateral putamen and right caudate, 
      and increased ReHo in right caudate and left putamen. Greater increase of fALFF 
      in the left putamen correlated with less improvement in positive symptoms. Thus, 
      abnormalities of spontaneous neural activity in chronic schizophrenia is at least 
      partly due to a medication effect. The observed post-treatment increase in 
      striatal intrinsic activity may reflect counter-therapeutic functional adaptation 
      to dopamine D2 receptor occupancy required for medication effects on psychosis.
FAU - Hu, Mao-Lin
AU  - Hu ML
AD  - Department of Psychiatry, the Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China.
AD  - Division of Molecular Imaging and Neuropathology, New York State Psychiatric 
      Institute and Departments of Psychiatry and Radiology, Columbia University, New 
      York, NY, USA.
AD  - Mental Health Institute of the Second Xiangya Hospital, Central South University, 
      Chinese National Clinical Research Center on Mental Disorders (xiangya), Chinese 
      National Technology Institute on Mental Disorders, Hunan Key Laboratory of 
      Psychiatry and Mental Health, Changsha, Hunan, China.
FAU - Zong, Xiao-Fen
AU  - Zong XF
AD  - Department of Psychiatry, the Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China.
AD  - Division of Molecular Imaging and Neuropathology, New York State Psychiatric 
      Institute and Departments of Psychiatry and Radiology, Columbia University, New 
      York, NY, USA.
AD  - Mental Health Institute of the Second Xiangya Hospital, Central South University, 
      Chinese National Clinical Research Center on Mental Disorders (xiangya), Chinese 
      National Technology Institute on Mental Disorders, Hunan Key Laboratory of 
      Psychiatry and Mental Health, Changsha, Hunan, China.
FAU - Zheng, Jun-Jie
AU  - Zheng JJ
AD  - Key Laboratory for NeuroInformation of the Ministry of Education, School of Life 
      Science and Technology, University of Electronic Science and Technology of China, 
      Chengdu, China.
FAU - Pantazatos, Spiro P
AU  - Pantazatos SP
AD  - Division of Molecular Imaging and Neuropathology, New York State Psychiatric 
      Institute and Departments of Psychiatry, Columbia University, New York, NY, USA.
FAU - Miller, Jeffrey M
AU  - Miller JM
AD  - Division of Molecular Imaging and Neuropathology, New York State Psychiatric 
      Institute and Departments of Psychiatry and Radiology, Columbia University, New 
      York, NY, USA.
FAU - Li, Zong-Chang
AU  - Li ZC
AD  - Department of Psychiatry, the Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China.
FAU - Liao, Yan-Hui
AU  - Liao YH
AD  - Department of Psychiatry, the Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China.
AD  - Department of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for 
      Neuroscience, David Geffen School of Medicine, Los Angeles, CA, USA.
FAU - He, Ying
AU  - He Y
AD  - Department of Psychiatry, the Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China.
FAU - Zhou, Jun
AU  - Zhou J
AD  - Department of Psychiatry, the Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China.
FAU - Sang, De-En
AU  - Sang DE
AD  - Department of Radiology, Henan Mental Hospital, the Second Affiliated Hospital of 
      Xinxiang Medical University, Xinxiang, Henan, China.
FAU - Zhao, Hong-Zeng
AU  - Zhao HZ
AD  - Department of Radiology, Henan Mental Hospital, the Second Affiliated Hospital of 
      Xinxiang Medical University, Xinxiang, Henan, China.
FAU - Lv, Lu-Xian
AU  - Lv LX
AD  - Department of Psychiatry, Henan Mental Hospital, the Second Affiliated Hospital 
      of Xinxiang Medical University, Xinxiang, Henan, China.
AD  - Henan Key Lab of Biological Psychiatry, Henan Mental Hospital, Xinxiang Medical 
      University, Xinxiang, Henan, China.
FAU - Tang, Jin-Song
AU  - Tang JS
AD  - Department of Psychiatry, the Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China.
AD  - Department of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for 
      Neuroscience, David Geffen School of Medicine, Los Angeles, CA, USA.
FAU - Mann, J John
AU  - Mann JJ
AD  - Division of Molecular Imaging and Neuropathology, New York State Psychiatric 
      Institute and Departments of Psychiatry and Radiology, Columbia University, New 
      York, NY, USA.
FAU - Chen, Xiao-Gang
AU  - Chen XG
AD  - Department of Psychiatry, the Second Xiangya Hospital, Central South University, 
      Changsha, Hunan, China.
AD  - Mental Health Institute of the Second Xiangya Hospital, Central South University, 
      Chinese National Clinical Research Center on Mental Disorders (xiangya), Chinese 
      National Technology Institute on Mental Disorders, Hunan Key Laboratory of 
      Psychiatry and Mental Health, Changsha, Hunan, China.
LA  - eng
GR  - K01 MH108721/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20161004
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Antipsychotic Agents)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/pharmacology/*therapeutic use
MH  - Brain/*drug effects/physiopathology
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Risperidone/pharmacology/*therapeutic use
MH  - Schizophrenia/*drug therapy/physiopathology
MH  - Young Adult
PMC - PMC5048418
EDAT- 2016/10/05 06:00
MHDA- 2018/07/11 06:00
PMCR- 2016/10/04
CRDT- 2016/10/05 06:00
PHST- 2016/06/24 00:00 [received]
PHST- 2016/09/09 00:00 [accepted]
PHST- 2016/10/05 06:00 [entrez]
PHST- 2016/10/05 06:00 [pubmed]
PHST- 2018/07/11 06:00 [medline]
PHST- 2016/10/04 00:00 [pmc-release]
AID - srep34287 [pii]
AID - 10.1038/srep34287 [doi]
PST - epublish
SO  - Sci Rep. 2016 Oct 4;6:34287. doi: 10.1038/srep34287.